Fig. 3: Clinical outcomes for IDH2-mutated AML patients without baseline mutations in NPM1 or FLT3-ITD and the association with residual IDH2 variants.
From: Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Cumulative incidence of relapse on the left and overall survival on the right for patients based on the presence (IDH2 NGS MRDpos) or absence (IDH2 NGS MRDneg) of residual IDH2 variants.
